Detailed Information on Publication Record
2019
Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
ARRIGO, Mattia, Jiří PAŘENICA, Eva GANOVSKÁ, Marie PAVLUSOVA, Alexander MEBAZAA et. al.Basic information
Original name
Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
Authors
ARRIGO, Mattia (250 France, guarantor), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Eva GANOVSKÁ (703 Slovakia), Marie PAVLUSOVA (203 Czech Republic) and Alexander MEBAZAA (250 France)
Edition
IJC HEART & VASCULATURE, CLARE, ELSEVIER IRELAND LTD, 2019, 2352-9067
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14110/19:00109543
Organization unit
Faculty of Medicine
UT WoS
000462184100037
Keywords in English
Bio-adrenomedullin; Acute coronary syndrome; Acute heart failure; Pulmonary edema
Tags
International impact, Reviewed
Změněno: 11/5/2020 09:13, Mgr. Tereza Miškechová
Abstract
V originále
Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had step-wise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 +/- 10.6 vs. 27.6 +/- 2.1 vs. 22.5 +/- 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 +/- 2.7 vs. 21.8 +/- 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS. (c) 2019 Published by Elsevier B.V.
Links
| MUNI/A/1250/2017, interní kód MU |
|